Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): soc

A cost-impact analysis explores the societal cost savings of subcutaneous foslevodopa/foscarbidopa treatment for advanced Parkinson's disease over a 5-year horizon. The model aggregates expected costs for direct medical, non-medical, and informal care, using real-world data from the Adelphi source and applying unit costs for the UK, France, Germany, Spain, and Canada. The analysis, authored by K. Ray Chaudhuri and last updated in April 2026, projects a net cumulative saving of €96,273 per patient.

Use Cases

• Compare societal cost savings of a specific Parkinson's treatment across different healthcare systems based on the five-country analysis.
• Model the relationship between patient OFF-time and care costs based on the severity-progression framework described.
• Inform healthcare policy decisions regarding drug reimbursement by evaluating offsetting savings in professional and informal care costs.

Strengths

• Analysis is based on a 5-year time horizon model, providing a medium-term cost perspective.
• Model incorporates real-world data from the Adelphi source to estimate resource use.
• Results include specific projected savings, such as a net cumulative saving of €96,273 per patient.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the five included countries.

Provenance

Source

figshare

Collection Method

A developed model aggregated expected costs from a cohort, using resource use estimates from the Adelphi real-world data source and indirect costs from published literature.

Time Range

5-year time horizon

Freshness

Last updated 2026-04-28 09:31:53; freshness should be verified.

Geography

UK, France, Germany, Spain, Canada